BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24571613)

  • 1. Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma.
    Jiang L; Zhu W; Streicher K; Morehouse C; Brohawn P; Ge X; Dong Z; Yin X; Zhu G; Gu Y; Ranade K; Higgs BW; Yao Y; Huang J
    BMC Cancer; 2014 Feb; 14():131. PubMed ID: 24571613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
    Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
    Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Zhang W; Li T; Hu B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
    Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
    Hou G; Lu Z; Bi Y; Deng J; Yang X
    Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NF-YA Overexpression in Lung Cancer: LUSC.
    Bezzecchi E; Ronzio M; Dolfini D; Mantovani R
    Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31744190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
    Yang K; Wu Y
    BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of periostin isoform pattern in non-small cell lung cancer.
    Morra L; Rechsteiner M; Casagrande S; von Teichman A; Schraml P; Moch H; Soltermann A
    Lung Cancer; 2012 May; 76(2):183-90. PubMed ID: 22079858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
    Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
    Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic analysis of IGF2BP family members in non-small-cell lung cancer.
    Gong L; Liu Q; Jia M; Sun X
    Hum Genomics; 2024 Jun; 18(1):63. PubMed ID: 38867248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis.
    Tian Y; Wang J; Wen Q; Su G; Sun Y
    Aging (Albany NY); 2021 May; 13(9):12691-12709. PubMed ID: 33973529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the Role and Regulation Mechanism of hsa-miR-147b in Lung Squamous Cell Carcinoma Based on The Cancer Genome Atlas Database.
    Ke D; Guo Q; Fan TY; Xiao X
    Cancer Biother Radiopharm; 2021 Apr; 36(3):280-291. PubMed ID: 33112657
    [No Abstract]   [Full Text] [Related]  

  • 13. Survival-associated alternative splicing signatures in non-small cell lung cancer.
    Zhao D; Zhang C; Jiang M; Wang Y; Liang Y; Wang L; Qin K; Rehman FU; Zhang X
    Aging (Albany NY); 2020 Apr; 12(7):5878-5893. PubMed ID: 32282333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival-associated N
    Qu J; Wang L; Jiang M; Wei Z; Fu G; Zhang X
    BMC Cancer; 2021 Nov; 21(1):1265. PubMed ID: 34814861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p.
    Lu W; Zhang H; Niu Y; Wu Y; Sun W; Li H; Kong J; Ding K; Shen HM; Wu H; Xia D; Wu Y
    Mol Cancer; 2017 Jul; 16(1):118. PubMed ID: 28697764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.
    Sepesi B; Nelson DB; Mitchell KG; Gibbons DL; Heymach JV; Vaporciyan AA; Swisher SG; Roszik J
    Ann Thorac Surg; 2018 Jun; 105(6):1621-1626. PubMed ID: 29510096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC).
    Storti CB; de Oliveira RA; de Carvalho M; Hasimoto EN; Cataneo DC; Cataneo AJM; De Faveri J; Vasconcelos EJR; Dos Reis PP; Cano MIN
    Exp Mol Pathol; 2020 Feb; 112():104354. PubMed ID: 31837325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
    Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
    BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer.
    You Q; Guo H; Xu D
    Drug Des Devel Ther; 2015; 9():5087-97. PubMed ID: 26366059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.